Evaluating the Clinical Efficacy of Zoledronic Acid in the Prevention and Treatment of Osteoporosis in Postmenopausal Women, Compared with Conventional Medications
Background: Due to the development of drugs, regarding this matter that customers of health services are unable to assess the clinical and financial aspects of medical technologies, evaluating the clinical efficacy of drugs is very important. This study aimed to evaluate the clinical efficacy of zol...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Isfahan University of Medical Sciences
2015-02-01
|
| Series: | مجله دانشکده پزشکی اصفهان |
| Subjects: | |
| Online Access: | http://jims.mui.ac.ir/index.php/jims/article/view/3294 |
| Summary: | Background: Due to the development of drugs, regarding this matter that customers of health services are unable to assess the clinical and financial aspects of medical technologies, evaluating the clinical efficacy of drugs is very important. This study aimed to evaluate the clinical efficacy of zoledronic acid in the prevention and treatment of postmenopausal osteoporosis.
Methods: In this systematic review, the Cochrane, PubMed and Google scholar databases were searched using the keywords: “bone mineral density, male osteoporosis, zoledronic acid postmenopausal women osteoporosis”. Inclusion criteria were all menopausal women at risk of or suffering from osteoporosis that used zoledronic acid, at least once, for the prevention or treatment of osteoporosis. Desired outcomes included reduced bone fractures, bone resorption and bone turnover markers, increased bone density, and significant improvement in health-related quality of life in patients with a fracture. The included studies were randomized clinical trials in English language.
Findings: Using zoledronic acid significantly increased bone marrow density (BMD) at the total hip, lumbar spine, femoral neck, hip trochanter, and the distal radius; it reduced the incidence of hip fractures, morphometric vertebral fractures, vertebral fractures, any clinical fracture, clinical vertebral fractures, and risk of non-vertebral fracture; also, decreased bone turnover markers in the intervention group compared with the controls.
Conclusion: According to safety and clinical effectiveness of zoledronic acid, using this medication in the prevention and treatment of osteoporosis in postmenopausal women is recommended. |
|---|---|
| ISSN: | 1027-7595 1735-854X |